EC Number   |
Inhibitors |
Structure |
|---|
    6.2.1.3 | (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoic acid |
competitive inhibitor of palmitoleic acid activation |
   |
| 6.2.1.3 | 2-Bromopalmitate |
inhibition can be overcome by addition of phospholipid vesicles |
|
| 6.2.1.3 | 2-bromopalmitoyl-CoA |
inhibition can be overcome by addition of phospholipid vesicles |
|
| 6.2.1.3 | 5'-deoxy-5'-[([(1E)-5-[2-(methoxycarbonyl)phenyl]-5-oxopent-1-en-1-yl]sulfonyl)amino]adenosine |
mechanism of covalent inhibition |
|
| 6.2.1.3 | 5'-deoxy-5'-[([(1E)-5-[2-(methoxycarbonyl)phenyl]hexa-1,5-dien-1-yl]sulfonyl)amino]adenosine |
mechanism of covalent inhibition |
|
| 6.2.1.3 | 5'-deoxy-5'-[([4-[2-(methoxycarbonyl)phenyl]-4-oxobutanoyl]sulfamoyl)amino]adenosine |
mechanism of covalent inhibition |
|
| 6.2.1.3 | 5'-deoxy-5'-[([4-[2-(methoxycarbonyl)phenyl]pent-4-enoyl]sulfamoyl)amino]adenosine |
mechanism of covalent inhibition |
|
| 6.2.1.3 | 5'-O-([4-[2-(methoxycarbonyl)phenyl]-4-oxobutanoyl]sulfamoyl)adenosine |
mechanism of covalent inhibition |
|
| 6.2.1.3 | 5'-O-([4-[2-(methoxycarbonyl)phenyl]pent-4-enoyl]sulfamoyl)adenosine |
mechanism of covalent inhibition |
|
| 6.2.1.3 | Ag+ |
isoform Facl1 shows 64% residual activity and isoform Facl2 shows 71% residual activity at 1 mM |
|
